310 related articles for article (PubMed ID: 31627059)
41. Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors.
Nam G; Jung JM; Park HJ; Baek SY; Baek KS; Mok HY; Kim DE; Jung YH
Bioorg Med Chem; 2019 Aug; 27(15):3408-3420. PubMed ID: 31235266
[TBL] [Abstract][Full Text] [Related]
42. Discovery and optimisation studies of antimalarial phenotypic hits.
Mital A; Murugesan D; Kaiser M; Yeates C; Gilbert IH
Eur J Med Chem; 2015 Oct; 103():530-8. PubMed ID: 26408453
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
[TBL] [Abstract][Full Text] [Related]
44. Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups.
Krieger V; Hamacher A; Gertzen CGW; Senger J; Zwinderman MRH; Marek M; Romier C; Dekker FJ; Kurz T; Jung M; Gohlke H; Kassack MU; Hansen FK
J Med Chem; 2017 Jul; 60(13):5493-5506. PubMed ID: 28574690
[TBL] [Abstract][Full Text] [Related]
45. Identification and characterization of small molecule inhibitors of a class I histone deacetylase from Plasmodium falciparum.
Patel V; Mazitschek R; Coleman B; Nguyen C; Urgaonkar S; Cortese J; Barker RH; Greenberg E; Tang W; Bradner JE; Schreiber SL; Duraisingh MT; Wirth DF; Clardy J
J Med Chem; 2009 Apr; 52(8):2185-7. PubMed ID: 19317450
[TBL] [Abstract][Full Text] [Related]
46. Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6).
Yao L; Ramanujulu PM; Poulsen A; Ohlson S; Dymock BW
Bioorg Med Chem Lett; 2018 Aug; 28(15):2636-2640. PubMed ID: 29945795
[TBL] [Abstract][Full Text] [Related]
47. The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity.
Negmeldin AT; Pflum MKH
Bioorg Med Chem Lett; 2017 Aug; 27(15):3254-3258. PubMed ID: 28648461
[TBL] [Abstract][Full Text] [Related]
48. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
[TBL] [Abstract][Full Text] [Related]
49. Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.
Bieliauskas AV; Weerasinghe SV; Negmeldin AT; Pflum MK
Arch Pharm (Weinheim); 2016 May; 349(5):373-82. PubMed ID: 27062198
[TBL] [Abstract][Full Text] [Related]
50. Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.
Gaisina IN; Tueckmantel W; Ugolkov A; Shen S; Hoffen J; Dubrovskyi O; Mazar A; Schoon RA; Billadeau D; Kozikowski AP
ChemMedChem; 2016 Jan; 11(1):81-92. PubMed ID: 26592932
[TBL] [Abstract][Full Text] [Related]
51. Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.
Chu-Farseeva YY; Mustafa N; Poulsen A; Tan EC; Yen JJY; Chng WJ; Dymock BW
Eur J Med Chem; 2018 Oct; 158():593-619. PubMed ID: 30243158
[TBL] [Abstract][Full Text] [Related]
52. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
53. Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors.
ElHady AK; Shih SP; Chen YC; Liu YC; Ahmed NS; Keeton AB; Piazza GA; Engel M; Abadi AH; Abdel-Halim M
Bioorg Chem; 2020 May; 98():103742. PubMed ID: 32199305
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
55. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
56. Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells.
Zhang K; Yao Y; Tu Z; Liao C; Wang Z; Qiu Y; Chen D; Hamilton DJ; Li Z; Jiang S
Future Med Chem; 2020 Feb; 12(4):311-323. PubMed ID: 31782319
[No Abstract] [Full Text] [Related]
57. One-pot, multi-component synthesis and structure-activity relationships of peptoid-based histone deacetylase (HDAC) inhibitors targeting malaria parasites.
Diedrich D; Stenzel K; Hesping E; Antonova-Koch Y; Gebru T; Duffy S; Fisher G; Schöler A; Meister S; Kurz T; Avery VM; Winzeler EA; Held J; Andrews KT; Hansen FK
Eur J Med Chem; 2018 Oct; 158():801-813. PubMed ID: 30245402
[TBL] [Abstract][Full Text] [Related]
58. A structure-activity relationship study of the antimalarial and antileishmanial activities of nonpeptide macrocyclic histone deacetylase inhibitors.
Guerrant W; Mwakwari SC; Chen PC; Khan SI; Tekwani BL; Oyelere AK
ChemMedChem; 2010 Aug; 5(8):1232-5. PubMed ID: 20533500
[No Abstract] [Full Text] [Related]
59. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo.
Li Y; Quan J; Song H; Li D; Ma E; Wang Y; Ma C
Bioorg Chem; 2021 Sep; 114():105081. PubMed ID: 34153811
[TBL] [Abstract][Full Text] [Related]
60. Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
Sharma C; Oh YJ; Park B; Lee S; Jeong CH; Lee S; Seo JH; Seo YH
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
